Evidence
Research labels and false product claims
FDA’s consumer page describes research-labelled products, false pharmacy details, and misleading claims.
Food and Drug Administration (FDA), US
Read FDA’s product concernsResearch wording does not establish a plan for medical care.
Read the product claims alongside the care and pharmacy details.
Myth to check
Research wording is a mark of medical quality.
Rethink that tirzepatide assumption
A research-only label does not establish a reviewed medicine or proper care. The US medicine regulator, the FDA, warns about products sold for human use under that wording.
As of 26 September 2026, FDA warns against research-labelled tirzepatide products marketed to people with dosing instructions.
FDA warns that these products could harm people and that their quality is unknown.
Under the federal rule checked on 26 September 2026, a pharmacy needs a prescription from someone allowed to prescribe before supplying a prescription medicine.
A payment page does not replace that review.
Ask who assesses you and how questions reach that person.
The 26 September 2026 check found no generic version of tirzepatide with FDA approval.
A version of a brand drug with its own approval is called a generic. A compounded preparation, made to order, is a different category.
A seller saying “the same as the approved drug” does not prove it. FDA warns about sellers making that claim for medicines made to order.
FDA has reported compounded tirzepatide labels carrying false pharmacy names; some name a pharmacy that does not exist.
Ask for the pharmacy’s identity and match it to the state pharmacy record.
A very low price alone cannot tell you whether a service is legitimate.
The Federal Trade Commission warns about a seller who accepts only bank or wire transfers, digital money, a payment app, or gift cards. A demand to pay only in those ways is a sign of a likely scam.
Ask for clear written billing and refund terms before committing to care.
Evidence
FDA’s consumer page describes research-labelled products, false pharmacy details, and misleading claims.
Food and Drug Administration (FDA), US
Read FDA’s product concernsEvidence
The FTC’s payment alert explains why an insistence on these methods is a reason to pause.
Federal Trade Commission, Consumer Advice
Read the FTC payment alert